通策醫療(600763.SH):入駐浙江大學校友企業總部經濟園購買相關物業
格隆匯12月31日丨通策醫療(600763.SH)公佈,公司擬購買浙大創業研究院物業資產。標的為餘政工出〔2020〕16號地塊(178-3號地塊、D區塊)D4-1#、D4-2#,預測繪建築面積為2948.87平方米;餘政工出〔2019〕29號地塊(178-2號地塊、B區塊)B3幢1-18層,預測繪建築面積為34733.54平方米;餘政工出〔2019〕28號地塊(178-1號地塊、C區塊)C4幢部分物業,預估建築面積約為3117.59平方米,合計3份物業,預估合作單價(人民幣)1.2萬元/㎡,總成交價為4.896億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.